Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Medicenna Therapeutics Corp (MDNA)

Medicenna Therapeutics Corp (MDNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,933
  • Shares Outstanding, K 69,637
  • Annual Sales, $ 0 K
  • Annual Income, $ -7,600 K
  • 60-Month Beta 1.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.49
Trade MDNA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.14
  • Most Recent Earnings $-0.04 on 07/28/23
  • Latest Earnings Date 11/03/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate -0.05
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.05
  • Prior Year -0.05
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1513 +3.77%
on 11/01/23
0.3160 -50.32%
on 10/02/23
-0.1379 (-46.76%)
since 09/29/23
3-Month
0.1513 +3.77%
on 11/01/23
0.4673 -66.40%
on 08/02/23
-0.3023 (-65.82%)
since 08/01/23
52-Week
0.1513 +3.77%
on 11/01/23
0.8388 -81.28%
on 05/02/23
-0.5751 (-78.55%)
since 11/01/22

Most Recent Stories

More News
Could CRISPR Therapeutics Help You Become a Millionaire?

The gene-editing stock still has plenty of promise.

VRTX : 401.08 (+0.23%)
MDNA : 0.1570 (-13.16%)
CRSP : 55.89 (+1.49%)
Medicenna Announces Closing of Public Offering of Units Raising US$20 Million to Advance Pipeline

TORONTO and HOUSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.39 (+0.42%)
Medicenna Announces Pricing of US$20 Million Public Offering of Units

TORONTO and HOUSTON, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA, TSX: MDNA), a clinical...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.39 (+0.42%)
Medicenna Announces the Launch of a Marketed Underwritten Public Offering of Units

TORONTO and HOUSTON, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (Nasdaq: MDNA, TSX: MDNA), a clinical...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.39 (+0.42%)
Medicenna to Announce First Quarter Fiscal 2023 Financial Results and Operational Highlights on Monday, August 15, 2022

TORONTO and HOUSTON, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.39 (+0.42%)
Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

-- Tumor control was achieved in four of ten evaluable patients with advanced solid tumors unresponsive to other treatments enrolled in the ABILITY Study’s...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.39 (+0.42%)
Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights

--Cash runway extended late into calendar Q2 2023 --Tumor control achieved following MDNA11 treatment in 3 out of 8 patients enrolled in first 3 dose...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.39 (+0.42%)
Medicenna Strengthens Intellectual Property Protection for Superkine Platform with Issuance of U.S. Patent

Patent covers composition and methods of treating degenerative diseases via administration of IL-4 and IL-13 Empowered SuperkinesDelivery of selected Bcl-2...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.39 (+0.42%)
Medicenna to Announce Fiscal Year 2022 Financial Results and Operational Highlights on Wednesday, June 22, 2022

TORONTO and HOUSTON, June 07, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.39 (+0.42%)
Medicenna Presents Phase 1/2 ABILITY Study Data Highlighting MDNA11’s Favorable Clinical Profile at the 2022 Frontiers in Cancer Immunotherapy Meeting

-- New data show that MDNA11 boosted the lymphocyte population by 2-fold without inducing significant increases in eosinophils (associated with toxicity) ...

MDNA : 0.1570 (-13.16%)
MDNA.TO : 2.39 (+0.42%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Medicenna Therapeutics Corp is a clinical stage immuno-oncology company. It is engaged in developing engineered versions of IL-2, IL4 and IL13 cytokines called Superkines and Empowered Cytokines ECs for the treatment of cancer. Medicenna Therapeutics Corp is based in Toronto, Canada.

See More

Key Turning Points

3rd Resistance Point 0.2361
2nd Resistance Point 0.2180
1st Resistance Point 0.1875
Last Price 0.1570
1st Support Level 0.1389
2nd Support Level 0.1208
3rd Support Level 0.0903

See More

52-Week High 0.8388
Fibonacci 61.8% 0.5762
Fibonacci 50% 0.4951
Fibonacci 38.2% 0.4139
Last Price 0.1570
52-Week Low 0.1513

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar